Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Second generation antihistamine without sedative or antimuscarinic effect. Use in allergic rhinitis and conjunctivitis and urticaria. Oral administration once daily. ( AEMPS 2016, Wolthers 2013, Scaglione 2012, Conen 2011, Church 2011)
At the date of last update we found no published data on its excretion in breast milk.
Its lack of sedative effect because it does not cross the blood-brain barrier (Scaglione 2012, Church 2011) and its pharmacokinetic profile (Togawa 2016, AEMPS 2016, Sádaba 2013), -high percentage of plasma protein binding and volume of distribution and medium oral bioavailability-, make it unlikely to cause problems for the infant.
Until more data on this drug in relation to breastfeeding are known, safer alternatives are preferable, especially during the first month and in the case of mothers of premature infants.